United States-based contract research organisation Vial announced on Sunday that it has named Dr Neeraj Agarwal as scientific advisor for the company's Oncology CRO.
Dr Agarwal is a genitourinary cancer specialist and has been the overall study chair of multiple Phase I, Phase II, and Phase III trials and serves as a steering committee member of numerous other studies. He was named senior director of Clinical Research Innovation at the Huntsman Cancer Institute, University of Utah, where he holds multiple other leadership positions. He is a consultant to the US FDA's Oncology Drug Advisory Committee (ODAC) and heads early therapeutics in the SWOG genitourinary cancers committee.
Dr Agarwal said: "Over the last two decades, the entire process of conducting clinical trials has exponentially grown cumbersome. It is critical for this process to become more efficient to improve administrative work for the investigating teams, make it easier for our patients to enrol, improve the accrual timeline, and expedite and decrease the cost of drug development."
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study